Morepen Laboratories Limited — Updates, 12-05-2025: Amendment(s)

Morepen Laboratories Limited has announced a board meeting that approved audited standalone and consolidated financial results, reporting consolidated revenue of Rs. 1811.58 Cr and net profit of Rs. 118.02 Cr for the year. A final dividend of Rs. 0.20 per share was approved, subject to shareholder approval. The transfer of the Medical Devices Business to Morepen Medipath Limited has been postponed to April 1, 2025. The subsidiary plans to set up a wholly owned step-down subsidiary in Dubai to boost its global medical device presence. New Cost and Internal Auditors were appointed for FY 2025-26. After promoter-led dilution in Dr. Morepen Limited, Morepen’s holding dropped to 80%, and it acquired an 80% stake in Quick Med Private Limited, expanding into pharma distribution and healthcare logistics.